No matter how much you love these speculative winners, you don’t have a gain until you actually ring the register.

Citi is holding firm on its Sell rating for Hims & Hers Health, Inc. (NYSE:HIMS), according to a report released on June 3, keeping a $30 price target even as the company moves to expand its ...

Hers reports on harmful hair care ingredients. Avoid sulfates, parabens, silicones, and certain oils for healthier hair.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Drugmaker Novo Nordisk said it is halting its agreement with telehealth company Hims & Hers after less than two months, ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its way into Europe and wants to build more personalized drugs for its ...

Novo Nordisk exits obesity-drug partnership with Hims & Hers, cites compounding concerns Hims wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight ...

Start your journey to fuller-looking, thicker hair with a range of effective hair loss treatment options available through Hims & Hers - it's 100% online. No doctor's office visit needed ...

The partnership forged by Novo Nordisk (NVO) and Hims & Hers (HIMS) in April appeared to bring together two giant brands in ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...